{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:35:16Z","timestamp":1791588916506,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,29]]},"DOI":"10.7759\/cureus.107961","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:36:46Z","timestamp":1777466206000},"source":"Crossref","is-referenced-by-count":1,"title":["Convergent Oncostatin M and IL-31 Signaling in Chronic Pruritic Dermatoses: A Neuroimmune Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Perspective"],"prefix":"10.7759","author":[{"given":"Michelle","family":"Tashjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica K","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Ruppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne I","family":"Riskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.08.020","article-title":"Health-related QOL and economic burden of chronic pruritus","volume":"141","author":"Whang KA","year":"2021","unstructured":"Whang KA, Khanna R, Williams KA, Mahadevan V, Semenov Y, Kwatra SG. Health-related QOL and economic burden of chronic pruritus. J Invest Dermatol. 2021, 141:754-60.e1. 10.1016\/j.jid.2020.08.020","journal-title":"J Invest Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the International Forum for the Study of Itch","volume":"87","author":"St\u00e4nder S","year":"2007","unstructured":"St\u00e4nder S, Weisshaar E, Mettang T, et al.. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007, 87:291-4. 10.2340\/00015555-0305","journal-title":"Acta Derm Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2351487","article-title":"Unmet needs in treating itch: reaching beyond eczema","volume":"35","author":"Brooks SG","year":"2024","unstructured":"Brooks SG, Yosipovitch G. Unmet needs in treating itch: reaching beyond eczema. J Dermatolog Treat. 2024, 35:2351487. 10.1080\/09546634.2024.2351487","journal-title":"J Dermatolog Treat"},{"key":"ref4","article-title":"Prurigo nodularis and the pain cascade: understanding the pathogenesis and approach to management","volume":"19","author":"Burshtein J","year":"2026","unstructured":"Burshtein J, Burshtein A, Schlesinger T. Prurigo nodularis and the pain cascade: understanding the pathogenesis and approach to management. J Clin Aesthet Dermatol. 2026, 19:11-6.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.36518\/2689-0216.1644","article-title":"Presentations of cutaneous disease in various skin pigmentations: chronic atopic dermatitis","volume":"5","author":"Nguyen C","year":"2024","unstructured":"Nguyen C, Thompson J, Nguyen DA, Wong CM, Scheufele CJ, Carletti M, Weis SE. Presentations of cutaneous disease in various skin pigmentations: chronic atopic dermatitis. HCA Healthc J Med. 2024, 5:103-11. 10.36518\/2689-0216.1644","journal-title":"HCA Healthc J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01081-0","article-title":"Cutaneous components leading to pruritus, pain, and neurosensitivity in atopic dermatitis: a narrative review","volume":"14","author":"St\u00e4nder S","year":"2024","unstructured":"St\u00e4nder S, Luger T, Kim B, et al.. Cutaneous components leading to pruritus, pain, and neurosensitivity in atopic dermatitis: a narrative review. Dermatol Ther (Heidelb). 2024, 14:45-57. 10.1007\/s13555-023-01081-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich S","year":"2021","unstructured":"Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021, 9:303. 10.3390\/vaccines9030303","journal-title":"Vaccines (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.967684","article-title":"The importance of TSLP in allergic disease and its role as a potential therapeutic target","volume":"10","author":"Cianferoni A","year":"2014","unstructured":"Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol. 2014, 10:1463-74. 10.1586\/1744666X.2014.967684","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.036","article-title":"Periostin activation of integrin receptors on sensory neurons induces allergic itch","volume":"31","author":"Mishra SK","year":"2020","unstructured":"Mishra SK, Wheeler JJ, Pitake S, et al.. Periostin activation of integrin receptors on sensory neurons induces allergic itch. Cell Rep. 2020, 31:107472. 10.1016\/j.celrep.2020.03.036","journal-title":"Cell Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2001925","article-title":"The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia","volume":"4","author":"Liu Q","year":"2011","unstructured":"Liu Q, Weng HJ, Patel KN, Tang Z, Bai H, Steinhoff M, Dong X. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal. 2011, 4:ra45. 10.1126\/scisignal.2001925","journal-title":"Sci Signal"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.008","article-title":"Itch: a paradigm of neuroimmune crosstalk","volume":"52","author":"Wang F","year":"2020","unstructured":"Wang F, Kim BS. Itch: a paradigm of neuroimmune crosstalk. Immunity. 2020, 52:753-66. 10.1016\/j.immuni.2020.04.008","journal-title":"Immunity"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627985","article-title":"Involvement of neuro-immune interactions in pruritus with special focus on receptor expressions","volume":"8","author":"Ruppenstein A","year":"2021","unstructured":"Ruppenstein A, Limberg MM, Loser K, Kremer AE, Homey B, Raap U. Involvement of neuro-immune interactions in pruritus with special focus on receptor expressions. Front Med (Lausanne). 2021, 8:627985. 10.3389\/fmed.2021.627985","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/life14020245","article-title":"Role of IL-4 and IL-13 in cutaneous T cell lymphoma","volume":"14","author":"Mazzetto R","year":"2024","unstructured":"Mazzetto R, Miceli P, Tartaglia J, Ciolfi C, Sernicola A, Alaibac M. Role of IL-4 and IL-13 in cutaneous T cell lymphoma. Life (Basel). 2024, 14:245. 10.3390\/life14020245","journal-title":"Life (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10254-003-0013-1","article-title":"Oncostatin M, a multifunctional cytokine","author":"Tanaka M","year":"2003","unstructured":"Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Reviews of Physiology, Biochemistry and Pharmacology. Amara SG, Bamberg E, Blaustein MP, et al. (ed): Springer, Berlin, Heidelberg; 2003. 149:39-52. 10.1007\/s10254-003-0013-1"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54124-1","article-title":"Structures of complete extracellular assemblies of type I and type II oncostatin M receptor complexes","volume":"15","author":"Zhou Y","year":"2024","unstructured":"Zhou Y, Stevis PE, Cao J, et al.. Structures of complete extracellular assemblies of type I and type II oncostatin M receptor complexes. Nat Commun. 2024, 15:9776. 10.1038\/s41467-024-54124-1","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and\u00a0novel therapeutics","volume":"190","author":"Liao V","year":"2024","unstructured":"Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and\u00a0novel therapeutics. Br J Dermatol. 2024, 190:798-810. 10.1093\/bjd\/ljae052","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2026.102031","article-title":"Oncostatin M drives multifaceted immune pathogenesis in atopic dermatitis-like inflammation via neutrophil-dependent mechanisms","volume":"0","author":"Park M","year":"2026","unstructured":"Park M, Jang J, Na K, et al.. Oncostatin M drives multifaceted immune pathogenesis in atopic dermatitis-like inflammation via neutrophil-dependent mechanisms. Genes Dis. 2026, 0:102031. 10.1016\/j.gendis.2026.102031","journal-title":"Genes Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.25.15760","article-title":"Signaling of type II oncostatin M receptor","volume":"272","author":"Auguste P","year":"1997","unstructured":"Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A, Gascan H. Signaling of type II oncostatin M receptor. J Biol Chem. 1997, 272:15760-4. 10.1074\/jbc.272.25.15760","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2024.104889","article-title":"Molecular and cellular pruritus mechanisms in the host skin","volume":"136","author":"Li L","year":"2024","unstructured":"Li L, Li ZE, Mo YL, et al.. Molecular and cellular pruritus mechanisms in the host skin. Exp Mol Pathol. 2024, 136:104889. 10.1016\/j.yexmp.2024.104889","journal-title":"Exp Mol Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 inhibition as a therapeutic approach for the management of chronic pruritic dermatoses","volume":"81","author":"Roh YS","year":"2021","unstructured":"Roh YS, Choi J, Sutaria N, Belzberg M, Kwatra MM, Kwatra SG. IL-31 inhibition as a therapeutic approach for the management of chronic pruritic dermatoses. Drugs. 2021, 81:895-905. 10.1007\/s40265-021-01521-1","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a\u00a0new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci IS","year":"2018","unstructured":"Ba\u011fci IS, Ruzicka T. IL-31: a\u00a0new key player in dermatology and beyond. J Allergy Clin Immunol. 2018, 141:858-66. 10.1016\/j.jaci.2017.10.045","journal-title":"J Allergy Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas F","year":"2014","unstructured":"Cevikbas F, Wang X, Akiyama T, et al.. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014, 133:448-60. 10.1016\/j.jaci.2013.10.048","journal-title":"J Allergy Clin Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang Q","year":"2008","unstructured":"Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008, 19:347-56. 10.1016\/j.cytogfr.2008.08.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091906","article-title":"Interleukin-31 and pruritic skin","volume":"10","author":"Furue M","year":"2021","unstructured":"Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021, 10:1906. 10.3390\/jcm10091906","journal-title":"J Clin Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang IH","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022, 13:1068260. 10.3389\/fimmu.2022.1068260","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen LK","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al.. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017, 171:217-28.e13. 10.1016\/j.cell.2017.08.006","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.07.010","article-title":"The role of Janus kinase signaling in the pathology of atopic dermatitis","volume":"152","author":"Guttman-Yassky E","year":"2023","unstructured":"Guttman-Yassky E, Irvine AD, Brunner PM, et al.. The role of Janus kinase signaling in the pathology of atopic dermatitis. J Allergy Clin Immunol. 2023, 152:1394-404. 10.1016\/j.jaci.2023.07.010","journal-title":"J Allergy Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113433","article-title":"Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch","volume":"42","author":"Takahashi S","year":"2023","unstructured":"Takahashi S, Ochiai S, Jin J, et al.. Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch. Cell Rep. 2023, 42:113433. 10.1016\/j.celrep.2023.113433","journal-title":"Cell Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-24-03","article-title":"Systematic reviews of effectiveness","author":"Tufanaru C","year":"2025","unstructured":"Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Systematic reviews of effectiveness. JBI Manual for Evidence Synthesis - 2024 Edition. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (ed): JBI, Adelaide, AU; 2025. 10.46658\/JBIMES-24-03"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1191","article-title":"IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis","volume":"92","author":"Nobbe S","year":"2012","unstructured":"Nobbe S, Dziunycz P, M\u00fchleisen B, Bilsborough J, Dillon SR, French LE, Hofbauer GF. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol. 2012, 92:24-8. 10.2340\/00015555-1191","journal-title":"Acta Derm Venereol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin","volume":"96","author":"Nattkemper LA","year":"2016","unstructured":"Nattkemper LA, Martinez-Escala ME, Gelman AB, Singer EM, Rook AH, Guitart J, Yosipovitch G. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol. 2016, 96:894-8. 10.2340\/00015555-2417","journal-title":"Acta Derm Venereol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim HJ","year":"2018","unstructured":"Kim HJ, Zeidi M, Bonciani D, Pena SM, Tiao J, Sahu S, Werth VP. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. 2018, 179:669-78. 10.1111\/bjd.16498","journal-title":"Br J Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4615","article-title":"Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation","volume":"178","author":"Boniface K","year":"2007","unstructured":"Boniface K, Diveu C, Morel F, et al.. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol. 2007, 178:4615-22. 10.4049\/jimmunol.178.7.4615","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe3037","article-title":"Oncostatin M can sensitize sensory neurons in inflammatory pruritus","volume":"13","author":"Tseng PY","year":"2021","unstructured":"Tseng PY, Hoon MA. Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med. 2021, 13:eabe3037. 10.1126\/scitranslmed.abe3037","journal-title":"Sci Transl Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1251031","article-title":"Oncostatin M suppresses IL31RA expression in dorsal root ganglia and interleukin-31-induced itching","volume":"14","author":"Suehiro M","year":"2023","unstructured":"Suehiro M, Numata T, Saito R, et al.. Oncostatin M suppresses IL31RA expression in dorsal root ganglia and interleukin-31-induced itching. Front Immunol. 2023, 14:1251031. 10.3389\/fimmu.2023.1251031","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly E","year":"2006","unstructured":"Sonkoly E, Muller A, Lauerma AI, et al.. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006, 117:411-7. 10.1016\/j.jaci.2005.10.033","journal-title":"J Allergy Clin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14391","article-title":"Pathophysiology of pruritus in primary localized cutaneous amyloidosis","volume":"174","author":"Tey HL","year":"2016","unstructured":"Tey HL, Cao T, Nattkemper LA, Tan VW, Pramono ZA, Yosipovitch G. Pathophysiology of pruritus in primary localized cutaneous amyloidosis. Br J Dermatol. 2016, 174:1345-50. 10.1111\/bjd.14391","journal-title":"Br J Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.05.033","article-title":"Nuclear IL-33 plays an important role in IL-31-mediated downregulation of FLG, keratin 1, and keratin 10 by regulating signal transducer and activator of transcription 3 activation in human keratinocytes","volume":"142","author":"Dai X","year":"2022","unstructured":"Dai X, Shiraishi K, Muto J, Utsunomiya R, Mori H, Murakami M, Sayama K. Nuclear IL-33 plays an important role in IL-31-mediated downregulation of FLG, keratin 1, and keratin 10 by regulating signal transducer and activator of transcription 3 activation in human keratinocytes. J Invest Dermatol. 2022, 142:136-44.e3. 10.1016\/j.jid.2021.05.033","journal-title":"J Invest Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11047.x","article-title":"Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide \u03b2-endorphin, via STAT3\/calcium axis in atopic dermatitis","volume":"167","author":"Lee CH","year":"2012","unstructured":"Lee CH, Hong CH, Yu WT, et al.. Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide \u03b2-endorphin, via STAT3\/calcium axis in atopic dermatitis. Br J Dermatol. 2012, 167:794-803. 10.1111\/j.1365-2133.2012.11047.x","journal-title":"Br J Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02545.x","article-title":"Functional effects of interleukin 31 in human primary keratinocytes","volume":"66","author":"Kasraie S","year":"2011","unstructured":"Kasraie S, Niebuhr M, Baumert K, Werfel T. Functional effects of interleukin 31 in human primary keratinocytes. Allergy. 2011, 66:845-52. 10.1111\/j.1398-9995.2011.02545.x","journal-title":"Allergy"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2609","article-title":"Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab","volume":"159","author":"Deng J","year":"2023","unstructured":"Deng J, Liao V, Parthasarathy V, et al.. Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab. JAMA Dermatol. 2023, 159:977-85. 10.1001\/jamadermatol.2023.2609","journal-title":"JAMA Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1113\/EP088584","article-title":"Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways","volume":"105","author":"Wang H","year":"2020","unstructured":"Wang H, Lei L, Hu J, Li Y. Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways. Exp Physiol. 2020, 105:1151-8. 10.1113\/EP088584","journal-title":"Exp Physiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.10.010","article-title":"Increased serum human \u03b2-defensin-2 levels in atopic dermatitis: relationship to IL-22 and oncostatin M","volume":"217","author":"Kanda N","year":"2012","unstructured":"Kanda N, Watanabe S. Increased serum human \u03b2-defensin-2 levels in atopic dermatitis: relationship to IL-22 and oncostatin M. Immunobiology. 2012, 217:436-45. 10.1016\/j.imbio.2011.10.010","journal-title":"Immunobiology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700461","article-title":"A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis","volume":"126","author":"Gazel A","year":"2006","unstructured":"Gazel A, Rosdy M, Bertino B, Tornier C, Sahuc F, Blumenberg M. A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis. J Invest Dermatol. 2006, 126:2647-57. 10.1038\/sj.jid.5700461","journal-title":"J Invest Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3505","article-title":"Oncostatin M induction of monocyte chemoattractant protein 1 is inhibited by anti-oncostatin M receptor beta monoclonal antibody KPL-716","volume":"100","author":"Richards CD","year":"2020","unstructured":"Richards CD, Gandhi R, Botelho F, Ho L, Paolini JF. Oncostatin M induction of monocyte chemoattractant protein 1 is inhibited by anti-oncostatin M receptor beta monoclonal antibody KPL-716. Acta Derm Venereol. 2020, 100:adv00197. 10.2340\/00015555-3505","journal-title":"Acta Derm Venereol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14279","article-title":"Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta","volume":"30","author":"Hashimoto T","year":"2021","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, et al.. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021, 30:804-10. 10.1111\/exd.14279","journal-title":"Exp Dermatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2007.09.002","article-title":"Oncostatin M receptor-\u03b2 mutations underlie familial primary localized cutaneous amyloidosis","volume":"82","author":"Arita K","year":"2008","unstructured":"Arita K, South AP, Hans-Filho G, et al.. Oncostatin M receptor-\u03b2 mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008, 82:73-80. 10.1016\/j.ajhg.2007.09.002","journal-title":"Am J Hum Genet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/653724","article-title":"A novel missense mutation in oncostatin M receptor beta causing primary localized cutaneous amyloidosis","volume":"2014","author":"Saeedi M","year":"2014","unstructured":"Saeedi M, Ebrahim-Habibi A, Haghighi A, Zarrabi F, Amoli MM, Robati RM. A novel missense mutation in oncostatin M receptor beta causing primary localized cutaneous amyloidosis. Biomed Res Int. 2014, 2014:653724. 10.1155\/2014\/653724","journal-title":"Biomed Res Int"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka T","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M, et al.. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017, 376:826-35. 10.1056\/NEJMoa1606490","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg JI","year":"2020","unstructured":"Silverberg JI, Pinter A, Pulka G, et al.. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020, 145:173-82. 10.1016\/j.jaci.2019.08.013","journal-title":"J Allergy Clin Immunol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg JI","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, et al.. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024, 404:445-60. 10.1016\/S0140-6736(24)01203-0","journal-title":"Lancet"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder S","year":"2025","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al.. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial. JAMA Dermatol. 2025, 161:147-56. 10.1001\/jamadermatol.2024.4796","journal-title":"JAMA Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra SG","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al.. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023, 389:1579-89. 10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen H","year":"2023","unstructured":"Sofen H, Bissonnette R, Yosipovitch G, et al.. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023, 57:101826. 10.1016\/j.eclinm.2023.101826","journal-title":"EClinicalMedicine"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.4950","article-title":"Vixarelimab in patients with prurigo nodularis: a randomized clinical trial","volume":"162","author":"St\u00e4nder S","year":"2026","unstructured":"St\u00e4nder S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF. Vixarelimab in patients with prurigo nodularis: a randomized clinical trial. JAMA Dermatol. 2026, 162:133-41. 10.1001\/jamadermatol.2025.4950","journal-title":"JAMA Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld M","year":"2016","unstructured":"Feld M, Garcia R, Buddenkotte J, et al.. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016, 138:500-8.e24. 10.1016\/j.jaci.2016.02.020","journal-title":"J Allergy Clin Immunol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.03.1078","article-title":"KPL-716, an anti-oncostatin M receptor \u03b2 (OSMR\u03b2) monoclonal antibody, reduces IL-31-induced scratching behavior in cynomolgus monkeys: establishment and optimization of a PK\/PD model","volume":"139","author":"Gandhi R","year":"2019","unstructured":"Gandhi R, Crowder K, Barrow K, Paolini JF. KPL-716, an anti-oncostatin M receptor \u03b2 (OSMR\u03b2) monoclonal antibody, reduces IL-31-induced scratching behavior in cynomolgus monkeys: establishment and optimization of a PK\/PD model. J Invest Dermatol. 2019, 139:S173. 10.1016\/j.jid.2019.03.1078","journal-title":"J Invest Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2023.02.061","article-title":"Oncostatin M induces nociceptive signaling in human dorsal root ganglia","volume":"24","author":"Mwirigi J","year":"2023","unstructured":"Mwirigi J, Franco-Enzastiga UM, Sankaranarayanan I, et al.. Oncostatin M induces nociceptive signaling in human dorsal root ganglia. J Pain. 2023, 24:16. 10.1016\/j.jpain.2023.02.061","journal-title":"J Pain"},{"key":"ref61","article-title":"Oncostatin M induces IL-33 through STAT3 pathway in normal human epidermal keratinocytes","volume":"135","author":"Tsuda H","year":"2015","unstructured":"Tsuda H, Komine M, Tominaga S, Ohtsuki M. Oncostatin M induces IL-33 through STAT3 pathway in normal human epidermal keratinocytes. J Invest Dermatol. 2015, 135:S74.","journal-title":"J Invest Dermatol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.03.278","article-title":"The oncostatin M receptor beta axis identified in prurigo nodularis","volume":"139","author":"Mikhak Z","year":"2019","unstructured":"Mikhak Z, St\u00e4nder S, Metze D, et al.. The oncostatin M receptor beta axis identified in prurigo nodularis. J Invest Dermatol. 2019, 139:S35. 10.1016\/j.jid.2019.03.278","journal-title":"J Invest Dermatol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301529R","article-title":"Blockade of OSMR\u03b2 signaling ameliorates skin lesions in a mouse model of human atopic dermatitis","volume":"38","author":"Komori T","year":"2024","unstructured":"Komori T, Hisaoka T, Kotaki A, Iwamoto M, Miyajima A, Esashi E, Morikawa Y. Blockade of OSMR\u03b2 signaling ameliorates skin lesions in a mouse model of human atopic dermatitis. FASEB J. 2024, 38:e23359. 10.1096\/fj.202301529R","journal-title":"FASEB J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470070-convergent-oncostatin-m-and-il-31-signaling-in-chronic-pruritic-dermatoses-a-neuroimmune-janus-kinase-signal-transducer-and-activator-of-transcription-jak-stat-perspective","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:36:47Z","timestamp":1777466207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470070-convergent-oncostatin-m-and-il-31-signaling-in-chronic-pruritic-dermatoses-a-neuroimmune-janus-kinase-signal-transducer-and-activator-of-transcription-jak-stat-perspective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.107961","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}